Blueprint Medicines

FDA approval tracker: several early decisions in May
FDA approval tracker: several early decisions in May
EP Vantage
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
Flag link:
Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
Fierce Pharma
Blueprint Medicines
Deciphera
FDA
GIST
Ayvakit
Qinlock
Flag link:
After a PhIII failure, the FDA delivers Blueprint an expected CRL
After a PhIII failure, the FDA delivers Blueprint an expected CRL
Endpoints
Blueprint Medicines
FDA
complete response letter
Ayvakit
gastrointestinal stromal tumors
Flag link:
A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind
A groundbreaking cancer drug nabs fast OK, giving Eli Lilly boasting rights as a rival speeds close behind
Endpoints
Eli Lilly
selpercatinib
Retevmo
FDA
cancer
Loxo Oncology
Blueprint Medicines
Flag link:
Blueprint’s voyage ends in disaster
Blueprint’s voyage ends in disaster
EP Vantage
Blueprint Medicines
Ayvakit
clinical trials
Flag link:
The crucial data readouts coming soon for small biotechs
The crucial data readouts coming soon for small biotechs
EP Vantage
clinical trials
Akebia
Blueprint Medicines
Genfit
TG Therapeutics
vadadustat
Ayvakit
elafibranor
Flag link:
Blueprint hits goal in midphase rare disease trial, teeing up pivotal study
Blueprint hits goal in midphase rare disease trial, teeing up pivotal study
Fierce Biotech
Blueprint Medicines
avapritinib
clinical trials
systemic mastocytosis
Flag link:
Go or no go? Esperion's double whammy and a look to priority reviews
Go or no go? Esperion's double whammy and a look to priority reviews
EP Vantage
FDA
Esperion Therapeutics
Acacia Pharma
Blueprint Medicines
Agile Therapeutics
Lundbeck
Sun Pharma
Biohaven
Durect Corporation
Flag link:
Racing Blueprint, Lilly drug gets priority review for RET hopeful
Racing Blueprint, Lilly drug gets priority review for RET hopeful
Fierce Biotech
Eli Lilly
FDA
Blueprint Medicines
selpercatinib
LOXO-292
thyroid cancer
non-small cell lung cancer
Flag link:
Blueprint gets first approval as FDA backs stomach cancer drug
Blueprint gets first approval as FDA backs stomach cancer drug
Pharmaforum
Blueprint Medicines
FDA
Ayvakit
stomach cancer
Flag link:
Ipsen doubles down on rare bone disease
Ipsen doubles down on rare bone disease
EP Vantage
Ipsen
FOP
BLU-782
Blueprint Medicines
Clementia Pharmaceuticals
Flag link:
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
WCLC
lung cancer
KRAS
AMG 510
Amgen
RET
Merck
Keytruda
AstraZeneca
Imfinzi
Blueprint Medicines
Eli Lilly
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
Flag link:
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
BioCentury
Blueprint Medicines
BLU-667
ASCO 2019
Eli Lilly
RET-altered cancer
LOXO-292
Flag link:
Blueprint posts 'impressive' data for lead candidate, but investor response tepid
Blueprint posts 'impressive' data for lead candidate, but investor response tepid
Biopharma Dive
Blueprint Medicines
clinical trials
avapritinib
gastrointestinal cancer
Flag link:
Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points
Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points
Endpoints
Loxo Oncology
Blueprint Medicines
medullary thyroid cancer
LOXO-292
BLU-667
Flag link:
Blueprint Medicines unveils preclinical data for rare bone disease program
Blueprint Medicines unveils preclinical data for rare bone disease program
BioCentury
Blueprint Medicines
BLU-782
fibrodysplasia
Flag link:
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Motley Fool
ASCO
Endocyte
Loxo Oncology
Blueprint Medicines
Nektar Therapeutics
Jounce Therapeutics
Flag link:
Alexion leaves Moderna, others behind in R&D shake-up
Alexion leaves Moderna, others behind in R&D shake-up
BioPharma Dive
Alexion
Moderna Therapeutics
Arbutus BioPharma
Blueprint Medicines
R&D
Flag link:

Pages